These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18987042)

  • 21. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

  • 22. Diabetes drugs offered fresh start.
    Ledford H
    Nature; 2010 Jul; 466(7305):420-1. PubMed ID: 20651662
    [No Abstract]   [Full Text] [Related]  

  • 23. New treatments for diabetes.
    Irony I; Parks MH; Meyer RJ
    N Engl J Med; 2007 May; 356(21):2221; author reply 2222-3. PubMed ID: 17526095
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel diabetes drugs to face higher hurdles?
    Opar A
    Nat Rev Drug Discov; 2007 Sep; 6(9):687-9. PubMed ID: 17907340
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 26. New treatments for diabetes.
    Raz I; Eldor R
    N Engl J Med; 2007 May; 356(21):2222; author reply 2222-3. PubMed ID: 17526096
    [No Abstract]   [Full Text] [Related]  

  • 27. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 28. Rosiglitazone and the FDA.
    Krall RL
    N Engl J Med; 2007 Oct; 357(17):1776-7; author reply 1777. PubMed ID: 17969232
    [No Abstract]   [Full Text] [Related]  

  • 29. A voyage of discovery.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
    [No Abstract]   [Full Text] [Related]  

  • 30. Rosiglitazone approved for treatment of type 2 diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120
    [No Abstract]   [Full Text] [Related]  

  • 31. Rethinking the appraisal and approval of drugs for type 2 diabetes.
    Naci H; Lehman R; Wouters OJ; Goldacre B; Yudkin JS
    BMJ; 2015 Oct; 351():h5260. PubMed ID: 26452524
    [No Abstract]   [Full Text] [Related]  

  • 32. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
    Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
    N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
    [No Abstract]   [Full Text] [Related]  

  • 33. Revisiting the rosiglitazone story--lessons learned.
    Rosen CJ
    N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
    [No Abstract]   [Full Text] [Related]  

  • 34. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
    Lotz N
    MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
    [No Abstract]   [Full Text] [Related]  

  • 35. [First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
    MMW Fortschr Med; 2000 Sep; 142(36):50. PubMed ID: 11021073
    [No Abstract]   [Full Text] [Related]  

  • 36. Rosiglitazone, marketing, and medical science.
    Moynihan R
    BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
    [No Abstract]   [Full Text] [Related]  

  • 37. The Avandia debate: an unhappy conclusion.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
    [No Abstract]   [Full Text] [Related]  

  • 38. Pediatric drug development programs for type 2 diabetes: A review.
    Christensen ML; Franklin BE; Momper JD; Reed MD
    J Clin Pharmacol; 2015 Jul; 55(7):731-8. PubMed ID: 25781151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Australian government tries to stop independent advice on diabetes drugs.
    Burton B
    BMJ; 2003 Dec; 327(7428):1368. PubMed ID: 14670876
    [No Abstract]   [Full Text] [Related]  

  • 40. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
    Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.